Skip to main content
Access every election story that matters
Enjoy unlimited digital access
$1.99
per week for 24 weeks
Access every election story that matters
Enjoy unlimited digital access
$1.99
per week
for 24 weeks
// //

COVID-19 vaccine maker Pfizer Inc will meet with federal health officials as soon as Monday to discuss the need for a booster dose of the coronavirus vaccine as it prepares to seek authorization, the company said on Sunday.

The meeting comes days after the drugmaker and its partner BioNTech SE announced plans to seek U.S. and European regulatory approval for a third dose of their COVID-19 shot amid the spread of variants and data they said showed heightened risk of infection six months after initial inoculation.

That push prompted a quick response from the U.S. Food and Drug Administration and the Centers for Disease Control and Prevention, saying Americans do not need a booster right now.

Story continues below advertisement

On Monday, Pfizer is scheduled to meet with representatives of the FDA, a company spokesperson said. The meeting was first reported by the Washington Post.

Representatives for the U.S. Department of Health and Human Services did not immediately respond to a request for comment.

Anthony Fauci, President Joe Biden’s chief medical adviser who also directs the National Institute of Allergy and Infectious Diseases, as well as the heads of the National Institutes of Health and the CDC were also among those invited to the briefing, which could move to another day, according to the Post’s report.

Fauci, in several television interviews on Sunday, said U.S. health officials were not dismissing the possible future need for boosters – especially as breakthrough infections among those who have been vaccinated have emerged – but that more data is needed for any formal recommendation.

“There’s a lot of dynamic things going on right now,” he told ABC News’ “This Week” program.

“There are studies being done now ongoing as we speak about looking at the feasibility about if and when we should be boosting people … there’s a lot of work going on to examine this in real time,” he added on CNN’s “State of the Union.”

Despite the FDA and CDC’s statement, “that doesn’t mean that we’re not very, very actively following and gathering all of this information to see if and when we might need it and if and when we do, we’ll have everything in place to do it.”

Story continues below advertisement

U.S. health officials are still struggling to get people in some areas to receive their initial inoculations as the highly contagious Delta variant has grown to be the nation’s dominant strain, with COVID-19 cases rising mostly among the unvaccinated.

European officials has also said vaccines currently seem protective against variants. Canada has also said it is monitoring variants and the possible need for boosters.

While some scientists have also questioned the need for booster shots, others have said they could be beneficial for the elderly and other vulnerable populations, although it is unclear when they would be needed.

Some public health experts have also expressed concern that authorizing boosters in wealthy developed nations while other countries are still struggling against initial inoculations will further exacerbate vaccine inequity.

Sign up for the Coronavirus Update newsletter to read the day’s essential coronavirus news, features and explainers written by Globe reporters and editors.

Your Globe

Build your personal news feed

  1. Follow topics and authors relevant to your reading interests.
  2. Check your Following feed daily, and never miss an article. Access your Following feed from your account menu at the top right corner of every page.

Follow topics related to this article:

View more suggestions in Following Read more about following topics and authors
Report an error
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

If you do not see your comment posted immediately, it is being reviewed by the moderation team and may appear shortly, generally within an hour.

We aim to have all comments reviewed in a timely manner.

Comments that violate our community guidelines will not be posted.

UPDATED: Read our community guidelines here

Discussion loading ...

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies